AI-generated summary
The authors studied 5XFAD mice, a model of Alzheimer's disease, treated with low-level light-emitting diode photobiomodulation starting at either 2 or 6 months of age. They report that early treatment was associated with reduced amyloid accumulation, neuronal loss and microgliosis, and with better cognitive performance on behavioral tests. The findings come from a mouse study, so they may not apply to humans.
- Who or what was studied
- 5XFAD mice used as an Alzheimer's disease model
- Limits stated in the abstract
- The study was conducted in mice, and the abstract does not report a total sample size or describe a control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on academic.oup.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.